GE Healthcare Technologies Inc

GEHC

Equity

ISIN US36266G1076 / Valor 123735674

NASDAQ (2025-04-04)

USD 60.51-16.0%

GE Healthcare Technologies Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

GE Healthcare Technologies Inc is a leading provider of medical imaging products and solutions, with a focus on delivering precise and efficient care across various disease states. Through the acquisition of MIM Software, the company has expanded its capabilities in AI-enabled imaging analysis and workflow tools, enhancing its offerings to healthcare professionals. GE Healthcare Technologies Inc is committed to leveraging technology to improve patient outcomes and streamline clinical workflows in the healthcare industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the third quarter of 2024, GE Healthcare Technologies Inc reported a revenue growth of 1% year-over-year, reaching $4.9 billion. This growth was consistent on both a reported and organic basis, with positive contributions from the U.S. and Pharmaceutical Diagnostics segments, despite market softness in China.

Net Income and Margins

GE Healthcare Technologies Inc's net income for the third quarter of 2024 was $470 million, up from $375 million in the prior year. The net income margin improved to 9.7% from 7.8%, while the adjusted EBIT margin increased to 16.3% from 15.4%, reflecting productivity gains and pricing benefits.

Earnings Per Share

The company reported diluted earnings per share (EPS) of $1.02 for the third quarter of 2024, compared to $0.83 in the previous year. Adjusted EPS was $1.14, up from $0.99, driven by improved EBIT and lower tax expenses.

Cash Flow

GE Healthcare Technologies Inc generated $742 million in cash flow from operating activities during the third quarter of 2024, an increase from $650 million in the prior year. Free cash flow also rose to $651 million, up from $570 million year-over-year.

2024 Outlook

The company has updated its full-year 2024 guidance, expecting organic revenue growth to trend toward the lower end of the 1% to 2% range. Adjusted EBIT margin is projected to be between 15.8% and 16.0%, with adjusted EPS anticipated to grow 8% to 11%, reaching between $4.25 and $4.35.

Summarized from source with an LLMView Source

Key figures

-31.2%1Y

%3Y

%5Y

Performance

27.8%1Y

29.7%3Y

29.7%5Y

Volatility